Divesiran

N/A

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameDivesiran
Drug Alias NameSLN-124
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceTransmembrane protease serine 6 inhibitors
TargetsTransmembrane protease serine 6
Therapy Area/IndicationsIron OverloadHemochromatosisMyelodysplastic Syndromes +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntradigm Corp
China Registration ClassN/A

Develop Information

Active CompaniesSilence TherapeuticsSilence Therapeutics Plc
Inactive CompaniesN/A
Active IndicationsIron OverloadHemochromatosisMyelodysplastic Syndromes +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A